{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:17:22Z","timestamp":1791404242281,"version":"4.3.3"},"reference-count":24,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0529600"],"award-info":[{"award-number":["2024ZD0529600"]}]},{"name":"the Major Project of Guangzhou National Laboratory","award":["GZNL2024A02003"],"award-info":[{"award-number":["GZNL2024A02003"]}]},{"name":"Plan on Enhancing Scientific Research in Guangzhou Medical University","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["82470040"],"award-info":[{"award-number":["82470040"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangzhou Science and Technology Plans","award":["2024A04J6495, 2024A03J1206, 2023B03J0407"],"award-info":[{"award-number":["2024A04J6495, 2024A03J1206, 2023B03J0407"]}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,3,10]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Florensocatib (formerly known as HSK31858) is a novel reversible inhibitor of dipeptidyl peptidase 1. We sought to determine the efficacy and safety of florensocatib in decreasing exacerbation frequency in Chinese adults with bronchiectasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The HOPE-BE trial was a phase 3, randomised, placebo-controlled trial which determines the efficacy and safety of high-dose florensocatib (40\u2005mg once daily)\n                      <jats:italic>versus<\/jats:italic>\n                      placebo in Chinese adults with bronchiectasis who had two or more exacerbations within the past year. Patients were randomly assigned in a 2:1 ratio to receive florensocatib 40\u2005mg or matching placebo once daily for 52\u2005weeks. We recorded demographics, medical history, bacterial infection status and quality-of-life and performed spirometry at baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We randomised 700 patients who were enrolled from 67 sites in mainland China between September 2024 and November 2025. 60.4% of patients were female. 559 (79.9%) and 141 (20.1%) of patients, respectively, had two and three or more exacerbations in the past year. The median (interquartile range) of 24-h sputum weight was 14.8 (29.3) g, and the median (interquartile range) of sputum purulence score was 5.0 (2.0). 192 (27.4%) patients were culture positive to\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      , and demonstrated significantly higher 24-h sputum volume and purulence score, and lower lung function and quality-of-life scores. Significant geographical variations were seen regarding comorbidity, blood eosinophil counts and sputum bacteriology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The baseline demographic characteristics of the HOPE-BE trial may provide important clues to future therapeutic efficacy assessment in adults with bronchiectasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00182-2026","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:55:14Z","timestamp":1775746514000},"page":"00182-2026","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Florensocatib in adults with bronchiectasis: the HOPE-BE trial protocol and baseline demographic characteristics"],"prefix":"10.1183","volume":"12","author":[{"given":"Nan-shan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun-chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-ren","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-feng","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-min","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-qiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-yin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-mo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-jie","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026082403351270000_12.4.00182-2026.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31767-7"},{"key":"2026082403351270000_12.4.00182-2026.2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jama.2025.2680","article-title":"Non-cystic fibrosis bronchiectasis in adults: a review","volume":"334","author":"Barker","year":"2025","journal-title":"JAMA"},{"key":"2026082403351270000_12.4.00182-2026.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC"},{"key":"2026082403351270000_12.4.00182-2026.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"2026082403351270000_12.4.00182-2026.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01126-2025"},{"key":"2026082403351270000_12.4.00182-2026.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02990-2020"},{"key":"2026082403351270000_12.4.00182-2026.7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbr.2017.07.014","article-title":"Spanish guidelines on treatment of bronchiectasis in adults","volume":"54","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"2026082403351270000_12.4.00182-2026.8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S2213-2600(25)00160-2","article-title":"Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study","volume":"13","author":"Sibila","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026082403351270000_12.4.00182-2026.9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.chest.2022.08.2216","article-title":"Long-term azithromycin in children with bronchiectasis unrelated to cystic fibrosis: treatment effects over time","volume":"163","author":"Vicendese","year":"2023","journal-title":"Chest"},{"key":"2026082403351270000_12.4.00182-2026.10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","article-title":"The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial","volume":"2","author":"Rogers","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026082403351270000_12.4.00182-2026.11","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.21037\/jtd-2025-289","article-title":"Dipeptidyl peptidase 1 inhibitors and neutrophilic inflammation in bronchiectasis: a narrative review","volume":"17","author":"Tang","year":"2025","journal-title":"J Thorac Dis"},{"key":"2026082403351270000_12.4.00182-2026.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00081-2025"},{"key":"2026082403351270000_12.4.00182-2026.13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/resp.12582","article-title":"Sputum matrix metalloproteinase-8 and -9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: clinical correlates and prognostic implications","volume":"20","author":"Guan","year":"2015","journal-title":"Respirology"},{"key":"2026082403351270000_12.4.00182-2026.14","first-page":"0958","article-title":"NLRP3 inflammasome activation modulates neutrophil extracellular trap formation and aggravates airway inflammation in bronchiectasis","volume":"8","author":"Chen","year":"2025","journal-title":"Research (Wash D C)"},{"key":"2026082403351270000_12.4.00182-2026.15","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0257-2024"},{"key":"2026082403351270000_12.4.00182-2026.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02444-z"},{"key":"2026082403351270000_12.4.00182-2026.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021713"},{"key":"2026082403351270000_12.4.00182-2026.18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082403351270000_12.4.00182-2026.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01551-2024"},{"key":"2026082403351270000_12.4.00182-2026.20","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/bcp.70027","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase-1 inhibitor, in healthy volunteers: an integrated phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study","volume":"91","author":"Wang","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"2026082403351270000_12.4.00182-2026.21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2213-2600(25)00019-0","article-title":"Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"13","author":"Zhong","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026082403351270000_12.4.00182-2026.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017"},{"key":"2026082403351270000_12.4.00182-2026.23","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205918"},{"key":"2026082403351270000_12.4.00182-2026.24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1513\/AnnalsATS.202302-133OC","article-title":"Quality-of-life bronchiectasis respiratory symptom scale predicts the risk of exacerbations in adults with bronchiectasis: a prospective observational study","volume":"21","author":"Gao","year":"2024","journal-title":"Ann Am Thorac Soc"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00182-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:35:19Z","timestamp":1787567719000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00182-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/23120541.00182-2026"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00182-2026","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}